X4 Pharmaceuticals
XFOR
15 hedge funds and large institutions have $161M invested in X4 Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.42% more ownership
Funds ownership: 0% → 0.42% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$28.1M |
| 2 |
O
OrbiMed
New York
|
+$26.3M |
| 3 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
+$26.3M |
| 4 |
SHI
SV Health Investors
Boston,
Massachusetts
|
+$26.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
Top Sellers
XFOR Hedge Fund Activity: Q4 2017 in Review
15 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2017, worth a combined $161M.
Buyers outnumbered sellers: 15 funds opened new XFOR positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $28.1M.
- 15 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $161M of X4 Pharmaceuticals stock for Q4 2017.
- 15 funds opened new X4 Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +15 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2017 was NEA Management Company, an estimated $28.1M added.
Based on aggregated 13F filings for Q4 2017.